Olivier Legrain, IBA’s CEO, comments: "To know that yet another country’s citizens will have access to proton therapy is a true joy. Swedish cancer patients can rest assured that their treatment center features state-of-the-art equipment, offering them the most refined modalities to date. IBA will continue to work with Skandion to ensure cancer loses ground in Sweden.”
About Proton Therapy
Ad Statistics
Times Displayed: 21862
Times Visited: 433 Stay up to date with the latest training to fix, troubleshoot, and maintain your critical care devices. GE HealthCare offers multiple training formats to empower teams and expand knowledge, saving you time and money
Proton Therapy is considered the most advanced and targeted cancer radiotherapy treatment due to its superior dose distribution and fewer side effects. Protons deposit the majority of their effective energy within a precisely controlled range, directly within the tumor, sparing healthy surrounding tissue. Higher doses can be delivered to the tumor without increasing the risk of side effects and long term complications, thereby improving patient outcomes and quality of life. Today, more than half of all proton therapy clinical facilities worldwide are equipped with IBA systems. This includes 18 proton therapy centers currently in operation and 16 additional centers under development.
While proton therapy today represents less than 1% of radiotherapy treatments, studies estimate that more than 17% of patients treated by radiotherapy would benefit from being treated by this technique.
About IBA
IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The company is the worldwide technology leader in the field of proton therapy, the most advanced form of radiation therapy available today. IBA’s proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full-scale proton therapy centers as well as compact, single room systems. In addition, IBA also has a radiation dosimetry business and develops particle accelerators for the medical world and industry.
Headquartered in Belgium and employing about 1100 people worldwide, IBA has installed systems across the world, from Europe and the US to emerging markets. IBA is listed on the panEuropean stock exchange EURONEXT. (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB). More information can be found at: www.ibaworldwide.com
About Skandionkliniken
The Skandionkliniken is the first clinic for proton therapy in Scandinavia, located in Uppsala. It is a national project, established in collaboration between the seven Swedish County Councils that have university hospitals. In 2006, the County Councils formed the Joint Authority of County Councils for Advanced Radiotherapy. The Joint Authority has the duty to build and operate the clinic, create conditions for optimal treatment and develop and evaluate the clinical activities. Construction was initiated in June 2011 and the first patient is expected to be treated in 2015. The clinic is designed at present for treatment of 1,000 patients per year, but with the option for future expansion.
